VoyForums
[ Show ]
Support VoyForums
[ Shrink ]
VoyForums Announcement: Programming and providing support for this service has been a labor of love since 1997. We are one of the few services online who values our users' privacy, and have never sold your information. We have even fought hard to defend your privacy in legal cases; however, we've done it with almost no financial support -- paying out of pocket to continue providing the service. Due to the issues imposed on us by advertisers, we also stopped hosting most ads on the forums many years ago. We hope you appreciate our efforts.

Show your support by donating any amount. (Note: We are still technically a for-profit company, so your contribution is not tax-deductible.) PayPal Acct: Feedback:

Donate to VoyForums (PayPal):

[ Login ] [ Contact Forum Admin ] [ Main index ] [ Post a new message ] [ Search | Check update time | Archives: 1, 2, [3], 4, 5 ]

[ Next Thread | Previous Thread | Next Message | Previous Message ]

Date Posted: 22:15:48 08/04/06 Fri
Author: President : Kiyoshi Morita
Subject: Management Message
In reply to: Daiichi Pharmaceutical Co., Ltd. 's message, "Agreement between Daiichi Pharmaceutical Co., Ltd. and the US Department of Justice" on 22:14:07 08/04/06 Fri

1.IR Policy

President : Kiyoshi Morita








1.IR Policy




President : Kiyoshi Morita
Daiichi Pharmaceutical's corporate philosophy is to contribute to the world's health by the development of innovative technologies and the widespread use of superior products. The Company's management vision is to establish a solid foundation in the first decade of the 21st century as an R&D-oriented global pharmaceutical company. To realize this vision, the Company has designated conformance with global standards and stakeholder-oriented management as the key principles on which to base its actions and business administration, and promotes transparency, independence, universality, and open-mindedness in all aspects of its activities.
However, Daiichi Pharmaceutical's stakeholders have varying expectations of the Company. Patients and healthcare professionals hope that the Company creates superior products that meet specific medical needs, and shareholders demand that the value of the Company continues to be increased. The Company is committed to filling these demands. Society considers, in addition to the observation of corporate ethics, contribution in such areas as environmental preservation, public welfare, and the advancement of art and culture as attributes of a good corporate citizen and quality company. Employees seek improvement of the working environment to facilitate individual self-fulfillment. Daiichi Pharmaceutical's vision of the Company's future comprises simultaneously meeting these expectations while continuing its ongoing pursuit of contributing to the world's health.

IR is one of the important components of Daiichi Pharmaceutical's corporate branding activities and the Company's efforts in this area focus on gaining a reputation for reliability and trustworthiness in the stock market by establishing appropriate short-term share prices and increasing the long-term total market value. Our basic stance is to create relationships built on trust through mutual communications with investors in the form of timely and accurate disclosure of corporate information coupled with investor feedback on the management system.

Daiichi Pharmaceutical's disclosure policy is to convey a balanced and realistic account of the Company's situation that includes any relevant negative information. The Company also proactively releases information beyond the boundary of the official disclosure system to heighten trust among investors.

In addition, investor feedback regarding the management system has enabled the Company to become more attuned to investors' expectations. It is vital that consensus be built between investors' and the Company's opinions, and that such consensus be reflected in the Company's activities. Daiichi Pharmaceutical intends to bolster its efforts as never before toward an approach in which information and opinions gained through communications with investors are surely used as reference by the Company.

Daiichi Pharmaceutical is endeavoring to establish shareholder relationships built on trust through continuous interaction with the stock market. We are creating this IR site in line with these efforts, and we hope that it will contribute to strengthening our relationships with investors, which are built on trust.






Certain information set forth in this web site may constitute forecasts regarding future business performance. The company makes no guarantees of assurance for the outcome of these forecasts as they include inherent uncertainties and risks. Please note that the actual future outcomes may differ from the stated target due to changes in the business environment, etc.
The English text that appears on this site was originally written in Japanese. If any discrepancies are found between the English and Japanese texts, the Japanese text will take precedence.



HOME b Corporate Profile b Investor Relations b News Release b Contact Us


Copyright (c) 2004 Daiichi Pharmaceutical Co.,Ltd. All Rights Reserved.



Website - http://ir.daiichipharm.co.jp/ManagementMessageU,locale,en_US.html

[ Next Thread | Previous Thread | Next Message | Previous Message ]
[ Contact Forum Admin ]

Forum timezone: GMT-8
VF Version: 3.00b, ConfDB:
Before posting please read our privacy policy.
VoyForums(tm) is a Free Service from Voyager Info-Systems.
Copyright © 1998-2019 Voyager Info-Systems. All Rights Reserved.